Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302
Francine M. Foss(Yale Cancer Center), Madeleine Duvic(Cancer Clinic), Chean Eng Ooi(Eisai (United States)), H. Miles Prince(Peter MacCallum Cancer Centre), Costas K. Yannakou(Epworth Hospital), Youn H. Kim(Stanford University), Myron S. Czuczman(Roswell Park Comprehensive Cancer Center), Dongyuan Xing, Nicholas Sauter(Eisai (United States)), Preeti Singh(Indian Agricultural Statistics Research Institute), Timothy M. Kuzel(Rush University)
Cited by 15
Related Papers
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657